汉族与维吾尔族50岁以上人群血清25羟维生素D3水平差异及其与骨质疏松症关系

目的分析新疆乌鲁木齐地区汉族与维吾尔族50岁以上人群血清25羟维生素D3水平差异,探讨其与骨质疏松症的关系。方法年龄50岁以上并完成血清骨转化指标及骨密度测定患者1 223例,汉族882例,维吾尔族341例。分析2个民族年龄、骨密度、血清25羟维生素D3及血清钙、磷水平的差异。结果汉族和维吾尔族原发性骨质疏松检出率比较差异无统计学意义(P>0.05);2个民族血清钙、磷水平在有无骨质疏松上差异无统计学意义(P>0.05);骨密度正常者,维吾尔族25羟维生素D3水平(30.19±19.67)nmol/L较汉族(48.50±27.97)nmol/L低(P<0.01);骨质疏松者,维吾尔族血清25羟维生素D3水平(31.82±20.79)nmol/L较汉族(47.41±26.56)nmol/L低(P<0.01);年龄与血清25羟维生素D3水平无相关性(r=0.007,P=0.817)。结论不同民族间血清25羟维生素D3水平有差异,其差异与骨质疏松无关。     

中国北方地区老年人冬季维生素D缺乏与骨量丢失

背景:中国北方地区老年人维生素D营养状态存在季节变化,冬春季维生素D缺乏严重。目的:分析沈阳市老年人冬季维生素D缺乏对骨量丢失的影响。方法:随机选择沈阳市60岁以上汉族健康老年人100名,于2000-03检测受试者血浆中25羟维生素D、甲状旁腺激素、钙和磷,清晨空腹2h尿中脱氧吡啶、钙、磷、肌酐,2000-03/2005-03两次检测髋部骨密度。结果与结论:基线时,血浆25羟维生素D浓度为(31.0±12.30)nmol/L,40%受试者低于25nmol/L;血浆甲状旁腺激素水平为(29.4±11.5)ng/L,血浆25羟维生素D浓度低于25nmol/L者甲状旁腺激素水平为(34.6±13.5)ng/L,血浆25羟维生素D浓度与甲状旁腺激素呈负相关(r=-0.479,P<0.0001)。5年后股骨颈骨丢失率为(3.05±4.07)%,大转子为(1.46±5.02)%,经体质量和身高变化率校正后,股骨颈骨丢失率与基线血浆25羟维生素D浓度呈负相关(r=-2.3,P=0.02),股骨颈骨丢失率基线血浆25羟维生素D浓度≤25nmol/L者高于浓度>25nmol/L者103%(F=7.2062,P=0.0085)。...     

孕妇血清25羟维生素D与妊娠期高血压的相关性研究

目的:研究孕妇血清25羟维生素D与妊娠期高血压之间的相关性。方法:采用酶联免疫分析法检测妊娠期高血压患者及正常孕妇在不同孕周的25羟维生素D水平,分析其与妊娠期高血压之间的相关性。结果:在妊娠16~21周和28~33周时,对照组25羟维生素D水平分别为(38.90±6.07)nmol/L和(49.00±12.92)nmol/L;A组为(37.80±6.63)nmol/L和(48.00±12.84)nmol/L;B组为(29.60±6.98)nmol/L和(34.80±7.76)nmol/L;C组为(23.90±3.89)nmol/L和(28.40±4.46)nmol/L。孕晚期的25羟维生素D水平较孕中期升高。A组、B组、C组在不同孕周的25羟维生素D水平为依次递减。B组、C组分别与对照组相比,孕妇血清25羟维生素D水平均显著降低,而A组与对照组相比,无明显差异(P>0.05)。结论:孕妇血清25羟维生素D水平与妊娠期高血压严重程度呈负相关。孕妇25羟维生素D水平的下降早于子痫前期临床症状的出现,可协助预测子痫前期的发生。     

中国北方地区老年人冬季维生素D缺乏与骨量丢失

背景：中国北方地区老年人维生素D营养状态存在季节变化,冬春季维生素D缺乏严重。目的：分析沈阳市老年人冬季维生素D缺乏对骨量丢失的影响。方法：随机选择沈阳市60岁以上汉族健康老年人100名,于2000-03检测受试者血浆中25羟维生素D、甲状旁腺激素、钙和磷,清晨空腹2h尿中脱氧吡啶、钙、磷、肌酐,2000-03/2005-03两次检测髋部骨密度。结果与结论：基线时,血浆25羟维生素D浓度为（31.0±12.30）nmol/L,40%受试者低于25nmol/L;血浆甲状旁腺激素水平为（29.4±11.5）ng/L,血浆25羟维生素D浓度低于25nmol/L者甲状旁腺激素水平为（34.6±13.5）ng/L,血浆25羟维生素D浓度与甲状旁腺激素呈负相关（r=-0.479,P〈0.0001）。5年后股骨颈骨丢失率为（3.05±4.07）%,大转子为（1.46±5.02）%,经体质量和身高变化率校正后,股骨颈骨丢失率与基线血浆25羟维生素D浓度呈负相关（r=-2.3,P=0.02）,股骨颈骨丢失率基线血浆25羟维生素D浓度≤25nmol/L者高于浓度〉25nmol/L者103%（F=7.2062,P=0.0085）。其他检测指标与骨丢失无显著相关性。说明老年人群冬季维生素D缺乏严重,维生素D缺乏促进骨量丢失,影响骨健康。     

中老年人维生素D水平对骨质疏松的影响及相关性分析

目的探讨中老年人维生素D水平对骨质疏松的影响及其相关性。方法选取2012年1月—12月行体检的中老年人80例,均行不同部位骨密度测定及维生素D水平检测。按照骨密度不同,分为骨质疏松组、骨量减少组及骨量正常组,而骨量减少组与骨量正常组又统称为非骨质疏松组。比较不同部位骨密度及维生素D表达水平,采用logistic分析探究维生素D与骨质疏松的相关性。结果本研究骨质疏松组19例,骨量减少组27例,骨量正常组34例。与骨质疏松组比较,骨量减少组、骨量正常组的腰2～腰3、股骨颈、大粗隆及Wards三角的骨密度升高,差异有统计学意义(P 0. 05)。骨质疏松组、骨量减少组、骨量正常组25羟维生素D水平分别为(53. 13±11. 71) mmol/L、(57. 24±12. 73) mmol/L、(57. 82±13. 53) mmol/L,比较差异无统计学意义(P 0. 05)。骨质疏松组与非骨质疏松组性别、年龄、25羟维生素D及碱性磷酸酶水平比较差异有统计学意义(P 0. 05)。logistic回归分析显示,25羟维生素D及碱性磷酸酶水平、年龄与性别为骨质疏松的高危因素。结论临床可通过骨密度测定及时诊断骨质疏松,而骨密度降低与维生素D缺乏、年龄、碱性磷酸酶降低有关。     

老年男性2型糖尿病患者甲状旁腺素、维生素D与骨密度的关系

目的 探讨老年男性2型糖尿病患者主要钙调激素甲状旁腺素(PTH)和维生素D的变化对骨密度的影响.方法 应用双能X线骨密度仪测定60例老年男性2型糖尿病患者的腰椎和髋部骨密度,检测血清中骨代谢及血糖相关的指标,并根据骨密度测定结果将60例老年男性2型糖尿病患者分为骨量减少组(32例)、骨质疏松组(12例)、正常组(16例),测定3组的血清PTH和25羟维生素D3,分析其与患者不同部位骨密度的相关性.结果 依据患者腰椎或髋部的骨密度值,骨质疏松的检出率为20.0％(12/60),骨量减少的检出率为53.3％(32/60).3组的血清PTH比较差异有统计学意义(F=3.32,P=0.043),骨量减少组、骨质疏松组与正常组相比,PTH水平明显上升[(44.87±10.62)、(50.24±20.32)μg/L与(36.96±12.36)μg/L,P均＜0.05].但25羟维生素D3浓度3组比较差异无统计学意义(P＞0.05).相关分析显示,PTH水平与髋部骨矿面密度(BMD)呈显著负相关(r=-0.224,P ＜0.05),与腰椎BMD无显著相关性(r=-0.187,P＞0.05).结论 老年男性2型糖尿病患者的髋部BMD与血清PTH浓度负相关.     

2型糖尿病患者血25羟维生素D的改变及其对糖代谢与骨密度的影响

目的 探讨2型糖尿病患者血25羟维生素D[25(OH)D]的改变及其对糖代谢与骨密度的影响.方法 选择我院住院的2型糖尿病患者258例,以25(OH)D为50 nmol/L为临界值进行分组,分为维生素D缺乏组[25 (OH)D＜50 nmol/L] 192例及维生素D相对不足组[25 (OH)D为50 ～ 70nmol/L]66例.双能X线骨密度仪(DXA)测量患者腰椎L2～L4及股骨颈骨密度,取腰椎Total值、股骨颈Neck和Total值为判定指标,采用稳态模型评估胰岛素抵抗(HOMA-IR)程度,收集分析患者糖代谢与骨代谢相关指标数据并进行统计分析.结果 258例2型糖尿病患者中骨质疏松57例,占22.1％.其中维生素D缺乏组与维生素D相对不足组的糖尿病病程、空腹胰岛素和胰岛素抵抗指数差异均有统计学意义[(7.98±1.09)、(3.77±1.21)年,(6.42±1.30)、(5.79±1.08) mU/L、(2.35±0.54)、(1.85±0.41),t值分别为4.849、3.871、2.705,P均＜0.05],而空腹血糖与糖化血红蛋白差异均无统计学意义(P均＞0.05),维生素D缺乏组与维生素D相对不足组的甲状旁腺激素、腰椎Total值、股骨颈Neck值、股骨颈Total值差异均有统计学意义[(36.51±7.59)、(32.02±6.89) ng/L,(0.87±0.14)、(0.99±0.12) g/cm2,(0.70±0.10)、(0.79±0.11)g/cm2,(0.84±0.14)、(0.97±0.15) g/cm2,t值分别为2.008、2.799、2.564、2.340,P均＜0.05].结论 2型糖尿病患者中普遍存在维生素D缺乏,维生素D的水平将影响糖尿病患者胰岛素抵抗和血糖控制及骨密度水平,导致骨质疏松发病率明显增加.因此,对糖尿病患者应进行常规维生素D检测,并对维生素D缺乏的患者及时给予维生素D补充治疗.     

1型糖尿病患儿血糖控制水平与骨密度及骨代谢标志物的相关性

目的探讨1型糖尿病患儿血糖控制水平与骨密度及骨代谢标志物的相关性。方法将37例1型糖尿病患儿按糖化血红蛋白检测结果分为控制良好组(糖化血红蛋白<9%,17例)和控制不良组(糖化血红蛋白≥9%,20例)。检测2组血清骨碱性磷酸酶的活性,血清胰岛素样生长因子-Ⅰ、全片段甲状旁腺素、25羟维生素D、钙、磷、肌酐和尿钙/尿肌酐比值、全血糖化血红蛋白的水平及骨密度。分析控制良好组全血糖化血红蛋白水平与骨密度及骨代谢标志物的相关性。结果 2组血清骨碱性磷酸酶活性,骨密度,血清胰岛素样生长因子-Ⅰ、25羟维生素D、钙、磷、肌酐水平比较差异均无统计学意义(P>0.05)。控制良好组全血糖化血红蛋白水平与血清骨碱性磷酸酶活性,骨密度,血清胰岛素样生长因子-Ⅰ、25羟维生素D、钙、磷、肌酐水平均无相关性(r=-0.24、-0.10、-0.16、-0.06、0.17、0.21、-0.22,均P>0.05)。结论在1型糖尿病患儿中血糖控制水平与骨密度及骨代谢标志物无相关性。 更多还原     

子痫前期患者血清25-羟维生素D水平检测的临床意义

目的 探讨子痫前期患者血清25-羟维生素D[25-（OH）D]水平检测的临床意义.方法 采用ELISA法及离子选择电极法测定200例妊娠期高血压疾病（妊娠高血压41例、子痫前期轻度30例、子痫前期重度131例）及300例正常晚期妊娠妇女血清25-（OH）D及钙的水平.结果 正常晚期妊娠组血清钙水平（2.46±0.11）mmol/L,25-（OH）D水平（51.37±13.19）nmol/L,均明显高于妊娠期高血压疾病组（P＜0.05）,妊娠期高血压疾病组血清钙水平（2.16±0.12）mmol/L,25-（OH）D水平（40.46±11.89）nmol/L;轻度子痫前期组血清钙水平（2.12±0.12）mmol/L,25-（OH）D水平（37.92±8.55）nmol/L,均明显高于重度子痫前期组（P＜0.05）,重度子痫前期组血清钙水平（1.89±0.14）mmol/L,25-（OH）D水平（28.05±10.4）nmol/L;晚发型重度子痫前期血清钙水平（1.86±0.13）mmol/L,25-（OH）D水平（27.12±9.1）nmol/L,均明显高于早发型（P＜0.05）,早发型血清钙水平（1.65±0.16）mmol/L,25-（OH）D水平（20.36±6.54）nmol/L;妊娠期高血压组与子痫前期轻度组血清钙及25-（OH）D水平差异无统计学意义（P〉0.05）.结论 低水平血清25-（OH）D可能与子痫前期的发生、发展有关.     

血清骨钙素与骨密度检测在中老年健康体检者中的应用及相关性分析

目的：研究中老年人群不同性别之间血清骨钙素水平是否存在差异,以及骨钙素水平与骨质疏松指标、其它骨代谢指标是否存在相关性。方法选取2011年1～8月中老年健康体检者270名,排除恶性肿瘤及慢性基础性疾病,其中男性101例,年龄50～89岁,中位年龄68岁,女性169例,年龄50～89岁,中位年龄64岁。使用骨密度仪进行骨密度检测,检测指标为T值;分别进行血清标本中骨钙素、25-羟维生素D、钙和磷检测。不同性别之间骨钙素水平的比较采用 Mann-Whitney检验,将骨钙素水平与骨质疏松风险指数、年龄、钙、磷和25-羟维生素 D的相关性进行 Spearman秩相关分析,P＜0.05为差异有统计学意义。结果270例中老年健康体检者的T值、骨钙素、25-羟维生素D、钙和磷水平范围分别为－3.5～－0.7（中位水平－1.6 ng／ml）,3.59～264.90 ng／ml（中位水平12.84 ng／ml）,4.0～34.0 ng／ml（中位水平10.5 ng／ml）,1.79～2.69 mmol／L（中位水平2.36 ng／ml）,0.43～2.89 mmol／L（中位水平1.12 ng／ml）;不同性别之间骨钙素存在差异,女性水平显著高于男性（P＝0.001）;血清骨钙素与血清磷水平存在相关性,相关系数为0.243（P＝0.001）;与骨质疏松风险指数存在负相关,相关系数为－0.197（P＝0.002）;与年龄（相关系数－0.157,P＝0.056）,25-羟维生素D（－0.156, P＝0.194）、血清钙（相关系数0.055,P＝0.368）均无相关性。结论在中老年人群中,女性骨钙素水平明显高于男性,在应用该指标时应该考虑性别因素;骨钙素与骨质疏松风险指数T存在相关性,可以用于评估骨质疏松。     

Hypovitaminosis D and response to supplementation in older patients with cystic fibrosis

This study reports serum 25-hydroxy vitamin D (25-(OH)D) levels, bone mineral content and bone maturation in 20 adolescent and adult patients with cystic fibrosis, and their response to the internationally recommended dose of supplementary vitamin D (800 iu/day; 20 micrograms/day). Serum 25-(OH)D values were below normal in 75 per cent of patients and serum alkaline phosphatase values, corrected for age, were increased in 60 per cent. Bone mineral content, measured by photon beam absorptiometry, was below the normal range in 45 per cent of patients and bone age retarded in 45 per cent. Following supplementation with vitamin D 40 per cent of patients failed to achieve normal serum 25-(OH)D levels. We concluded that hypovitaminosis D occurs frequently in older patients with cystic fibrosis and is accompanied by osteopenia and retarded bone maturation.     

中药补肾活骨方对去势骨质疏松大鼠骨代谢的影响(英文)

背景:中药补肾活骨方可有效防治骨质疏松症,但其具体的药理学机制仍不是很清楚。25-羟基维生素D3和1,25-二羟基维生素D3是调节骨吸收与骨形成的重要的偶联因子。目的:观察补肾中药对去势骨质疏松大鼠骨密度、骨生物力学、血清及肝肾组织中25-羟基维生素D3和1,25-二羟基维生素D3水平的影响。方法:健康雌性SD大鼠108只随机等分为假手术组、模型组和治疗组。后2组摘除双侧卵巢,导致雌激素缺失,从而诱导骨质疏松症模型。治疗组大鼠造模后以中药补肾活骨方2mL灌胃,2次/d。结果与结论:与模型组相比,治疗组股骨头骨密度明显提高(P<0.05),最大应力和最大负荷指数明显增强(P<0.05),血液、肝脏和肾脏组织中25-羟基维生素D3和1,25二羟基维生素D3水平明显提高(P<0.05);且接近于假手术组(P<0.05)。提示补肾中药在雌激素缺失早期即可在分子水平上调节25-羟基维生素D3和1,25-二羟基维生素D3的表达水平,激活骨代谢提高骨密度增强骨质量达到预防骨质疏松的作用。     

Hypovitaminosis D and Response to Supplementation in Older Patients with Cystic Fibrosis

This study reports serum 25-hydroxy vitamin D (25-(OH)D) levels,bone mineral content and bone maturation in 20 adolescent andadult patients with cystic fibrosis, and their response to theinternationally recommended dose of supplementary vitamin D(800iu/day; 20µg/day). Serum 25-(OH)D values were belownormal in 75 per cent of patients and serum alkaline phosphatasevalues, corrected for age, were increased in 60 per cent. Bonemineral content, measured by photon beam absorptiometry, wasbelow the normal range in 45 per cent of patients and bone ageretarded in 45 per cent. Following supplementation with vitaminD 40 per cent of patients failed to achieve normal serum 25-(OH)Dlevels. We conclude that hypovitaminosis D occurs frequentlyin older patients with cystic fibrosis and is accompanied byosteopenia and retarded bone maturation.     

汉、维吾尔族精神分裂症患者血清甲状腺激素水平对比研究

目的：探讨汉族与维族精神分裂症患者间甲状腺素T3、T4及TSH水平是否有差异。方法：141例精神分裂症患者作为实验组（汉族88例,维族53例）;192例在同一医院住院的非精神分裂症和非内分泌疾病患者作为对照组（汉族96例,维族96例）。对2组患者均进行血清T3、T4及TSH测定并进行比较。结果：2组中维族与汉族患者T3、T4及TSH水平测定均差异无统计学意义;2组间比较,实验组患者T3及T4均低于本民族的对照组（均P〈0.05）,TSH差异无显著性意义;结论：汉族、维族患者间血清甲状腺激素水平无显著变化;精神分裂症患者的甲状腺素有明显改变,可能由于神经递质遗传代谢紊乱所致。     

Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D.

A significant reduction in bone mineral density occurs in stroke patients on the hemiplegic side, correlating with the degree of paralysis and vitamin D deficiency due to malnutrition, sunlight deprivation, and immobilization-induced hypercalcemia, and increases the risk of hip fracture. We evaluated the effect of ipriflavone and 1alpha-hydroxyvitamin D3 [1alpha(OH)D3; vitamin D3] administration on bone mineral density preservation as compared with untreated controls. In a randomized and prospective study of 103 patients with hemiplegia after stroke (the mean duration of illness was 4.8 yr), 68 (34 patients in each group) were given 600 mg ipriflavone or 1 microg vitamin D3 daily for 12 mo, whereas the remaining 35 patients received no drug. Bone mineral density on the hemiplegic side decreased by 1.4% in the ipriflavone group, 3.8% in the vitamin D3 group, and 5.4% in the control group (P < .0001, ipriflavone v vitamin D3 and control). At baseline, all three groups of patients showed a 25-hydroxyvitamin D insufficiency, increased serum ionized calcium, and low levels of 1, 25-dihydroxyvitamin D, suggesting immobilization-induced hypercalcemia and inhibition of renal synthesis of 1, 25-dihydroxyvitamin D. After treatment, the serum 1, 25-dihydroxyvitamin D level increased by 139.9% in the ipriflavone group and by 26.9% in the vitamin D3 group. Significant decreases in the serum ionized calcium and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen, and increases in parathyroid hormone and bone Gla protein were observed in the ipriflavone group, whereas no changes occurred in the other two groups. One patient in the untreated group suffered a hip fracture, compared with none in the ipriflavone and vitamin D3 groups. These results suggest that ipriflavone is more efficacious than vitamin D3 in the prevention of decreased bone mineral density in hemiplegic stroke patients because it decreases serum calcium levels through inhibition of bone resorption and cause a subsequent increase in 1, 25-dihydroxyvitamin D concentration.     

中国汉族、维吾尔族、哈萨克族、蒙古族健康绝经后妇女维生素D受体基因多态性的分布

背景:维生素D受体基因在内切酶BsmⅠ,ApaⅠ,TaqⅠ作用下,呈限制性内切酶片段长度多态性,并且与骨密度密切相关熏而骨密度的变化对骨质疏松起着重要作用,但维生素D受体基因多态性与骨密度、骨质疏松相关性尚无定论。目的:分析在中国汉族、维吾尔族、哈萨克族、蒙古族绝经后妇女中与骨密度密切相关的维生素D受体基因多态性分布规律。设计:对比观察。单位:解放军总医院老年医学研究所。对象:选择2002-01/2003-12在解放军总医院进行健康体检的汉族绝经后妇女179名,平均年龄穴59±3雪岁。选择2001-01/2003-12于解放军兰州军区乌鲁木齐总医院老年科进行健康体检的维吾尔族、哈萨克族、蒙古族绝经后妇女者122,63,112名,平均年龄分别为(56±4),(55±3),(57±3)岁。均对检测项目知情同意。方法:应用聚合酶链反应限制性片段长度多态性技术确定维生素D受体基因BsmⅠ基因型,分析汉族、维吾尔族、哈萨克族和蒙古族绝经后妇女维生素D受体基因BsmⅠ多态性分布频率,并与已知的美国、澳大利亚、法国和日本相应数据进行比较。计数资料差异比较采用χ2检验。主要观察指标:汉族、维吾尔族、哈萨克族和蒙古族绝经后妇女维生素D受体基因BsmⅠ多态性分布频率,以及该分布特点与美国、澳大利亚、法国和日本相应数据比较结果。结果:汉族、维吾尔族、哈萨克族和蒙古族绝经后妇女维生素D受体基因bb基因型频率分别为90.5%,69.67%,38.1%和50%,BB基因型频率分别为0,4.1%,6.35%和4.46%,汉族与维吾尔族、哈萨克族和蒙古族维生素D受体基因型频率分布比较,差异明显穴P<0.01雪。哈萨克族与欧美人种比较熏维生素D受体基因型差异不明显,与日本、韩国人种差异明显(P<0.01)。结论:中国汉族与维吾尔族、哈萨克族和蒙古族绝经后妇女维生素D受体基因型多态性具明显种族差异性;哈萨克族维生素D受体基因型频率分布接近欧美人种,与日本、韩国人种差异明显。     

维汉不同民族神经症患者甲状腺激素水平对比研究

目的探讨维族与汉族神经症患者间甲状腺素T3、T4及TSH水平是否有差异。方法在自治区人民医院临床心理科住院的492例神经症患者作为实验组（汉族311例,维族181例）。在同一医院综合内科住院的非神经症患者共251例（汉族175维族76例）作为对照组。对所有人组者进行血清T3、T4及TSH测定并进行组间比较。统计方法采用方差分析及t检验。结果维族和汉族神经症患者组的T3及T4均低于本民族的对照组（P〈0．05）;无论是实验组,还是对照组中维、汉两族的T3、T4及TSH均无统计学差异（P〉O．05）。结论维族、汉族患者间血清甲状腺激素水平无显著性差异。     

Effects of Vitamin D Supplementation on Bone Health and Bone-related Parameters in HIV-infected Patients: A Systematic Review and Meta-analysis

PurposeThere is growing evidence that bone health is decreased in individuals with HIV infection. Vitamin D deficiency is also highly prevalent among HIV-infected patients. The literature was systematically reviewed to determine whether bone health and bone-related parameters may improve with vitamin D supplementation in HIV-infected individuals.MethodsFour databases were systematically searched for randomized clinical trials of vitamin D supplementation in HIV infection, published from January 1990 to September 2021. No language or publication restrictions were applied. Standardized mean differences (SMD) with 95% CIs are reported. A random-effects model was used to perform meta-analysis.FindingsTen studies met the inclusion criteria (N = 733 participants at study completion). The mean ages of the patients in the included trials ranged from 10 to 49 years. The meta-analysis indicated that with vitamin D supplementation, serum 25-hydroxy vitamin D (25[OH]D) level was significantly increased (SMD, 1.86; 95% CI, 1.02 to 2.70; I² = 94.4%), but there were no significant effects on levels of serum 1,25-dihydroxy vitamin D (1,25-[OH]₂D) (SMD, 0.29; 95% CI, –0.07 to 0.64; I² = 67.4%), total bone mineral density (SMD, 0.07; 95% CI, –0.23 to 0.37; I² = 00.0%), spine bone mineral density (SMD, 0.15; 95% CI, –0.19 to 0.49; I² = 17.3%), and parathyroid hormone level (SMD, –0.18; 95% CI, –0.37 to 0.02; I² = 1.2%) in HIV-infected patients.ImplicationsThis study showed that vitamin D supplementation can improve serum 25(OH)D in HIV-infected patients. The effects of vitamin D supplementation on other bone health–related parameters such as bone mineral density and parathyroid hormone in HIV-infected patients need to be further investigated in larger-scale, well-designed randomized, controlled trials.     

Increased bone resorption in the proximal femur in patients with hemiplegia

OBJECTIVES: To investigate the relationship between the proximal femoral bone mineral density and bone resorption markers, determinants of calcium metabolism and vitamin D levels in elderly stroke patients. DESIGN: A total of 80 patients and 20 controls were enrolled in the study. Bone mineral density measurements were obtained at the proximal femur. In all subjects, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, intact parathyroid hormone, osteocalcin, deoxypyridinoline, and ionized calcium concentrations were measured. Barthel Index and Motricity Index Leg Score were recorded all patients. RESULTS: The serum concentrations of deoxypyridinoline, intact parathyroid hormone, and the mean serum ionized calcium levels were significantly higher in patients with stroke than that of the control subjects. The mean serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations in patients were significantly lower than those of the control group (P < 0.05). The bone mineral density of proximal femurs of paretic limbs was decreased significantly compared with those of the control group (P < 0.05). There were significant correlations between the Z score of the hemiplegic side and the patients' Barthel Index, Motricity Index Leg Score, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, calcium, and deoxypyridinoline. CONCLUSIONS: This study provides clear evidence that decreased mobility, vitamin D status, and bone turnover variables in patients after stroke are important factors in the greater bone loss in the paretic leg.     

新疆维、汉两民族50岁及以上人群高血压患病率调查

目的了解新疆地区维、汉两民族≥50岁人群高血压的现患状况,为高血压的防治工作提供依据。方法采用分层随机多级整群抽样的方式,以现场问卷调查与入户调查相结合的方法,于2004年9月至2007年6月随机抽取新疆南疆≥50岁维、汉常住居民(1年以上)进行高血压的普查。共调查8583例,其中维吾尔族4936例,汉族3647例。结果新疆地区维、汉两民族≥50岁抽样人群高血压粗患病率为50.55%(标化率49.57%),高血压患病率随着年龄的增长而上升(χ2=78.303,P<0.05);其中汉族的患病率高于维族(χ2=4.829,P<0.05);抽样人群女性高于男性(χ2=8.862,P<0.05);维族女性高于维族男性,汉族男性高于维族男性,维族男性患病率最低(均P<0.05)。单纯性收缩期高血压粗患病率为14.63%(标化率13.74%)。结论新疆维、汉两民族≥50岁人群高血压的患病率较高,女性高于男性,汉族高于维族;单纯性收缩期高血压的患病率较低。